BRTX
BioRestorative Therapies, Inc. [BRTX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
BRTX Stock Summary
In the News
Insider Buying Alert: Lance Alstodt Acquires 4200 Shares of BioRestorative Therapies Inc (BRTX)
On July 25, 2023, Lance Alstodt, President, CEO, COB, and 10% Owner of BioRestorative Therapies Inc ( BRTX , Financial), made a significant purchase of 4200 shares of the company's stock. This move is noteworthy as insider buying can often be a positive indicator for the company's future performance.
BioRestorative Therapies, Inc. to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
5 Penny Stocks To Watch With Big News This Week
Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BioRestorative Therapies to Present in The Jan 26th Virtual Investor Summit Microcap Event
Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based therapies, announced today that management will be presenting at the virtual Investor Summit. During the presentation, BioRestorative Therapies Chief Executive Officer, Lance Alstdot, will highlight the Company's regenerative medicine platform and technology.
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
MELVILLE, NY., Sept. 28, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will be presenting at the Dawson James Securities 7th Annual Small Cap Growth Conference on October 12, 2022 at the Wyndham Grand Hotel in Jupiter, Florida.
4 Top Penny Stocks To Buy Right Now According To Insiders
Insiders decided to buy these penny stocks recently The post 4 Top Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference
MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that Lance Alstodt, its Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually from January 10-13, 2022.
Best Penny Stocks to Buy in January 2022? Check These 3 Out
Check these penny stocks out for your January 2022 watchlist The post Best Penny Stocks to Buy in January 2022? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
BioRestorative Therapies Stock (BRTX): Why The Price Surged Today
The stock price of BioRestorative Therapies Inc (NASDAQ: BRTX) increased by over 45% pre-market today. This is why it happened.
BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program
MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“ BioRestorative ” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance for a patent application for its metabolic ThermoStem® program.
BRTX Financial details
BRTX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 37.86 | 6.68 | 0.11 | 0.04 | 0.03 | |
| Net income per share | -4.27K | -920.83 | -17.13 | -25.21 | -4.98 | |
| Operating cash flow per share | -1.74K | -355.5 | -2.75 | -2.8 | -1.62 | |
| Free cash flow per share | -1.75K | -357.33 | -2.75 | -2.83 | -1.74 | |
| Cash per share | 40.08 | 0.09 | 4.28 | 17.7 | 4.08 | |
| Book value per share | -2.95K | -656.47 | -1.86 | 18.18 | 4.38 | |
| Tangible book value per share | -3.22K | -694.45 | -2.79 | 17.69 | 4.15 | |
| Share holders equity per share | -2.95K | -656.47 | -1.86 | 18.18 | 4.38 | |
| Interest debt per share | 2.51K | 662.43 | 8.99 | 2.09 | 0.09 | |
| Market cap | 10.56M | 389.24K | 19.75M | 5.15M | 9.95M | |
| Enterprise value | 14.59M | 8.14M | 21.48M | -15.2M | 8.57M | |
| P/E ratio | -0.84 | -0.02 | -1.61 | -0.17 | -0.55 | |
| Price to sales ratio | 95.09 | 2.99 | 256.48 | 112.06 | 83.05 | |
| POCF ratio | -2.07 | -0.06 | -10.05 | -1.55 | -1.69 | |
| PFCF ratio | -2.06 | -0.06 | -10.05 | -1.53 | -1.58 | |
| P/B Ratio | -1.22 | -0.03 | -14.83 | 0.24 | 0.63 | |
| PTB ratio | -1.22 | -0.03 | -14.83 | 0.24 | 0.63 | |
| EV to sales | 131.42 | 62.62 | 278.92 | -330.46 | 71.57 | |
| Enterprise value over EBITDA | -1.65 | -0.81 | -6.53 | 0.36 | -0.45 | |
| EV to operating cash flow | -2.86 | -1.18 | -10.93 | 4.57 | -1.46 | |
| EV to free cash flow | -2.85 | -1.17 | -10.93 | 4.52 | -1.36 | |
| Earnings yield | -1.19 | -46.04 | -0.62 | -5.81 | -1.81 | |
| Free cash flow yield | -0.48 | -17.87 | -0.1 | -0.65 | -0.63 | |
| Debt to equity | -0.48 | -0.61 | -3.6 | 0.03 | 0.02 | |
| Debt to assets | 3.48 | 5.29 | 1.1 | 0.03 | 0.02 | |
| Net debt to EBITDA | -0.46 | -0.77 | -0.53 | 0.48 | 0.07 | |
| Current ratio | 0.02 | 0.01 | 3.05 | 59.01 | 34.36 | |
| Interest coverage | -2.37 | -1.64 | -1.68 | -14.49 | -1.63K | |
| Income quality | 0.41 | 0.47 | 0.17 | 0.08 | 0.32 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 53.09 | 50.14 | 24.99 | 556.79 | 130.05 | |
| Research and developement to revenue | 13.63 | 13.25 | 11.39 | 15.85 | 29.33 | |
| Intangibles to total assets | 0.68 | 0.5 | 0.15 | 0.03 | 0.05 | |
| Capex to operating cash flow | 0 | 0.01 | 0 | 0.01 | 0.07 | |
| Capex to revenue | -0.12 | -0.27 | 0 | -0.67 | -3.67 | |
| Capex to depreciation | -0.05 | -0.16 | 0 | -0.34 | -3.65 | |
| Stock based compensation to revenue | 21.62 | 12.76 | 8.98 | 502.37 | 105.28 | |
| Graham number | 16.83K | 3.69K | 26.78 | 101.55 | 22.14 | |
| ROIC | 1.48 | 2.34 | -0.75 | -0.78 | -1.12 | |
| Return on tangible assets | -33.09 | -24.65 | -3.33 | -1.37 | -1.15 | |
| Graham Net | -3.31K | -730.49 | -3.64 | 16.99 | 3.91 | |
| Working capital | -9.07M | -13.65M | 2.14M | 21.1M | 14.69M | |
| Tangible asset value | -9.46M | -13.52M | -2M | 21.01M | 15.03M | |
| Net current asset value | -9.65M | -14.17M | -2.49M | 20.61M | 14.53M | |
| Invested capital | -0.48 | -0.61 | -3.6 | 0.03 | 0.02 | |
| Average receivables | 33.5K | 30.5K | 24.5K | 11K | 10.5K | |
| Average payables | 2.17M | 1.92M | 1.04M | 84.84K | 110.86K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 95.36 | 89.85 | 80.58 | 39.67 | 48.75 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 3.83 | 4.06 | 4.53 | 9.2 | 7.49 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 1.45 | 1.4 | 9.2 | -1.39 | -1.14 | |
| Capex per share | -4.39 | -1.83 | 0 | -0.03 | -0.12 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.01 | 0 | 0.01 | 0.02 | 0.01 | |
| Net income per share | -1.29 | -1.06 | -1.51 | -0.77 | -0.02 | |
| Operating cash flow per share | -0.4 | -0.43 | -0.63 | -0.29 | -0.26 | |
| Free cash flow per share | -0.39 | -0.5 | -0.65 | -0.3 | -0.26 | |
| Cash per share | 4.53 | 4.08 | 3.33 | 2.99 | 2.68 | |
| Book value per share | 4.67 | 4.38 | 3.63 | 3.19 | 2.81 | |
| Tangible book value per share | 4.52 | 4.15 | 3.42 | 3 | 2.65 | |
| Share holders equity per share | 4.67 | 4.38 | 3.63 | 3.19 | 2.81 | |
| Interest debt per share | 0.1 | 0.08 | 0.07 | 0.04 | 0.03 | |
| Market cap | 11.76M | 9.95M | 12.64M | 17.14M | 8.18M | |
| Enterprise value | 5.52M | 8.57M | 11.07M | 15.59M | 5.94M | |
| P/E ratio | -0.63 | -0.65 | -0.56 | -1.44 | -24.55 | |
| Price to sales ratio | 405.67 | 2.69K | 403.81 | 265.72 | 266.51 | |
| POCF ratio | -8.1 | -6.32 | -5.38 | -15.16 | -6.95 | |
| PFCF ratio | -8.24 | -5.56 | -5.25 | -14.78 | -6.88 | |
| P/B Ratio | 0.69 | 0.63 | 0.94 | 1.38 | 0.64 | |
| PTB ratio | 0.69 | 0.63 | 0.94 | 1.38 | 0.64 | |
| EV to sales | 190.48 | 2.32K | 353.72 | 241.69 | 193.6 | |
| Enterprise value over EBITDA | -1.2 | -1.79 | -1.93 | -5.07 | -1.91 | |
| EV to operating cash flow | -3.81 | -5.45 | -4.71 | -13.79 | -5.05 | |
| EV to free cash flow | -3.87 | -4.79 | -4.6 | -13.45 | -5 | |
| Earnings yield | -0.4 | -0.38 | -0.44 | -0.17 | -0.01 | |
| Free cash flow yield | -0.12 | -0.18 | -0.19 | -0.07 | -0.15 | |
| Debt to equity | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Debt to assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | |
| Net debt to EBITDA | 1.36 | 0.29 | 0.27 | 0.5 | 0.72 | |
| Current ratio | 23.55 | 34.36 | 27.18 | 14.82 | 13.51 | |
| Interest coverage | -159.83 | 272.35 | 317.25 | 32.4 | 50.34 | |
| Income quality | 0.31 | 0.36 | 0.41 | 0.38 | 0.4 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 125.85 | 1.08K | 137.35 | 34.31 | 73.63 | |
| Research and developement to revenue | 34.11 | 182.06 | 48.28 | 15.01 | 28.5 | |
| Intangibles to total assets | 0.03 | 0.05 | 0.06 | 0.06 | 0.05 | |
| Capex to operating cash flow | -0.02 | 0.14 | 0.03 | 0.03 | 0.01 | |
| Capex to revenue | 0.85 | -58.81 | -1.92 | -0.45 | -0.39 | |
| Capex to depreciation | 0.79 | -6.84 | -1.53 | -0.7 | -0.28 | |
| Stock based compensation to revenue | 106.02 | 826.56 | 106.68 | 23.03 | 48.65 | |
| Graham number | 11.65 | 10.2 | 11.1 | 7.42 | 1.07 | |
| ROIC | -0.26 | -0.25 | -0.41 | -0.23 | -0.12 | |
| Return on tangible assets | -0.27 | -0.24 | -0.42 | -0.24 | -0.01 | |
| Graham Net | 4.28 | 3.91 | 3.17 | 2.76 | 2.47 | |
| Working capital | 16.17M | 14.69M | 12.31M | 11.23M | 11.67M | |
| Tangible asset value | 16.47M | 15.03M | 12.71M | 11.65M | 12.09M | |
| Net current asset value | 15.97M | 14.53M | 12.19M | 11.15M | 11.63M | |
| Invested capital | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Average receivables | 30.5K | 30.5K | 16K | 20.5K | 32.15K | |
| Average payables | 423.37K | 319.7K | 131.74K | 184.32K | 251.7K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 139.66 | 389.19 | 46.01 | 34.88 | 115.21 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.64 | 0.23 | 1.96 | 2.58 | 0.78 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.28 | -0.24 | -0.42 | -0.24 | -0.01 | |
| Capex per share | 0.01 | -0.06 | -0.02 | -0.01 | 0 |
BRTX Frequently Asked Questions
What is BioRestorative Therapies, Inc. stock symbol ?
BioRestorative Therapies, Inc. is a US stock , located in Melville of Ny and trading under the symbol BRTX
What is BioRestorative Therapies, Inc. stock quote today ?
BioRestorative Therapies, Inc. stock price is $1.78 today.
Is BioRestorative Therapies, Inc. stock public?
Yes, BioRestorative Therapies, Inc. is a publicly traded company.
Company Profile
- Volume Average 32.82K
- Market Capitalization 8.38M
- Employee 10
- CEO Mr. Lance Alstodt
- Headquarters Melville,NY,US
- IPO Date 2012-12-05
-
Website
https://www.biorestorative.com 
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
